Recent News

• 11.06.2026 - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 11.05.2026 - Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
• 11.04.2026 - Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
• 10.28.2026 - Arcutis Appoints Rob Scott, MD to Board of Directors
• 10.27.2026 - Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
• 10.21.2026 - Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
• 10.09.2026 - Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
• 10.06.2026 - Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
• 10.02.2026 - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 09.29.2026 - Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options

Recent Filings

• 11.04.2026 - 8-K Current report
• 11.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.04.2026 - 3 Initial statement of beneficial ownership of securities
• 11.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.04.2026 - 3/A Initial statement of beneficial ownership of securities
• 11.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.04.2026 - 144 Report of proposed sale of securities
• 11.04.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2026 - EX-99.1 EX-99.1